Profound Medical Marks 500th Sonalleve Procedure Milestone
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Profound Medical ( (TSE:PRN) ) is now available.
On February 5, 2026, Profound Medical announced that PRO FAMILIA Specialist Hospital in Rzeszów, Poland had completed its 500th Sonalleve procedure, underscoring growing adoption of the company’s MRI-guided, incision-free treatment for common gynecologic conditions such as uterine fibroids and adenomyosis. The milestone, achieved at one of 10 operational Sonalleve sites across Europe, China and Southeast Asia where more than 4,000 women have been treated, highlights increasing international traction for Profound’s second product line alongside its TULSA-PRO prostate platform, supported by roughly $10 million in research funding over the past five years and reinforcing the company’s positioning in fertility-preserving, non-surgical care for women’s health.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on TSE:PRN Stock
According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.
The score is held back primarily by persistent heavy losses and large cash burn despite strong revenue growth and improving gross margins. Technicals are supportive with a clear uptrend, and recent earnings commentary and events point to improving commercial traction and strengthened liquidity, but financing/dilution risk and lack of profitable valuation anchors keep the overall score in the mid-range.
To see Spark’s full report on TSE:PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. Its flagship TULSA-PRO platform targets the full spectrum of prostate diseases with a one-session, non-surgical, radiation-free procedure, while its Sonalleve system is approved in multiple jurisdictions for non-invasive treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma, and is being explored for broader oncology applications.
Average Trading Volume: 21,545
Technical Sentiment Signal: Buy
Current Market Cap: C$336.1M
For an in-depth examination of PRN stock, go to TipRanks’ Overview page.
